- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07941518
Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)
The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.
Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.
Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.
Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Marta Ramon Krauel, MD PhD
- Número de teléfono: 71702 +34 932 804 000
- Correo electrónico: marta.ramon@sjd.es
Ubicaciones de estudio
-
-
-
Santiago de Compostela, España
- Hospital Clínico Universitario de Santiago
-
Contacto:
- Lidia Castro, MD
- Número de teléfono: +34 981 951 108
- Correo electrónico: lidia.castro.feijoo@sergas.es
-
-
Barcelona
-
Barcelona, Barcelona, España, 08950
- Hospital Sant Joan de Déu
-
Contacto:
- Marta Ramon Krauel, MD PhD
- Número de teléfono: 71702 +34 932 804 000
- Correo electrónico: marta.ramon@sjd.es
-
-
Madrid
-
Madrid, Madrid, España
- Hospital Universitario La Paz
-
Contacto:
- Isabel Casado, MD
- Correo electrónico: isabelgcasado@gmail.com
-
-
Valencia
-
Valencia, Valencia, España
- Hospital Universitario y Politécnico La Fe
-
Contacto:
- Moreno
- Correo electrónico: morenoframac@gva.es
-
-
Zaragoza
-
Zaragoza, Zaragoza, España
- Hospital Universitario Miguel Servet
-
Contacto:
- Labarta, MD
- Número de teléfono: 3476/3475 +34 976 765 500
- Correo electrónico: jilabarta@salud.aragon.es
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.
Descripción
Inclusion Criteria:
- Age between 3 and 16 years.
- Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
- Growth hormone treatment approved by the relevant local authorities and institution.
- Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.
Exclusion Criteria:
- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Weekly Long-Acting Growth Hormone
Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation. |
LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.
Otros nombres:
|
|
Daily Recombinant Human Growth Hormone
Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation. |
Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Percentage Total Body Fat
Periodo de tiempo: Baseline and 12 months
|
Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated. |
Baseline and 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Lean Body Mass
Periodo de tiempo: Baseline and 12 months
|
Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms. |
Baseline and 12 months
|
|
Change in body mass index standard deviation score (BMI-SDS)
Periodo de tiempo: Baseline and 12 months
|
Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables. |
Baseline and 12 months
|
|
Change in height standard deviation score (SDS)
Periodo de tiempo: Baseline and 12 months
|
Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables. |
Baseline and 12 months
|
|
Change in Waist Circumference
Periodo de tiempo: Baseline and 12 months
|
Change in waist circumference from baseline to 12 months, expressed in centimeters. |
Baseline and 12 months
|
|
Change in Waist-to-Hip Ratio
Periodo de tiempo: Baseline and 12 months
|
Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless. |
Baseline and 12 months
|
|
Change in Systolic Blood Pressure
Periodo de tiempo: Baseline and 12 months
|
Change in systolic blood pressure from baseline to 12 months, expressed in mmHg. |
Baseline and 12 months
|
|
Change in Diastolic Blood Pressure
Periodo de tiempo: Baseline and 12 months
|
Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg. |
Baseline and 12 months
|
|
Change in Fasting Glucose Concentration
Periodo de tiempo: Baseline and 12 months
|
Change in fasting blood glucose concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Fasting Insulin Concentration
Periodo de tiempo: Baseline and 12 months
|
Change in fasting blood insulin concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in HOMA-IR
Periodo de tiempo: Baseline and 12 months
|
Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Total Cholesterol Concentration
Periodo de tiempo: Baseline and 12 months
|
Change in total cholesterol concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in LDL Cholesterol Concentration
Periodo de tiempo: Baseline and 12 months
|
Change in LDL cholesterol concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in HDL Cholesterol Concentration
Periodo de tiempo: Baseline and 12 months
|
Change in HDL cholesterol concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Triglyceride Concentration
Periodo de tiempo: Baseline and 12 months
|
Change in Triglyceride concentration from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Change in Carotid Intima-Media Thickness
Periodo de tiempo: Baseline and 12 months
|
Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters. |
Baseline and 12 months
|
|
Change in Bone Mineral Density Z-Score
Periodo de tiempo: Baseline and 12 months
|
Change in bone mineral density Z-score measured by DXA from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Height Standard Deviation Score
Periodo de tiempo: Baseline and 12 months
|
Change in height standard deviation score (height SDS) from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Growth Velocity Standard Deviation Score
Periodo de tiempo: Baseline and 12 months
|
Change in growth velocity standard deviation score from baseline to 12 months. |
Baseline and 12 months
|
|
Change in Bone Age Minus Chronological Age
Periodo de tiempo: Baseline and 12 months
|
Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas. |
Baseline and 12 months
|
|
Change in IGF-1 standard deviation score
Periodo de tiempo: Baseline and 12 months
|
Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months. |
Baseline and 12 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- EOM-17-26
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .